Imatinib Sandoz (Imatinib Mesilate)

Imatinib mesilate binds to the ATP‑binding sites of BCR‑ABL, c‑KIT and PDGFR tyrosine kinases. This blocks phosphorylation of downstream signaling proteins, interrupting pathways that drive uncontrolled cell growth and survival, ultimately leading to apoptosis of malignant cells while sparing most normal tissues.

The exact dose of Imatinib Sandoz is determined by the prescribing physician based on the patient’s diagnosis, disease stage, weight, renal and hepatic function, and response to therapy. Physicians follow approved dosing guidelines but individualize the regimen for each patient.

Safety data for Imatinib Sandoz in pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant. Women of child‑bearing potential should use effective contraception and discuss risks with their healthcare provider.

To request Imatinib Sandoz, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Imatinib was the first BCR‑ABL inhibitor and remains a standard first‑line option for chronic myeloid leukemia and GIST. Newer agents such as dasatinib or nilotinib may offer faster molecular responses but can have different side‑effect profiles and drug‑interaction potentials. Choice of therapy depends on disease characteristics, patient tolerance and physician judgment.

Imatinib Sandoz tablets should be stored at room temperature, below 25 °C, in the original container to protect them from moisture and light. Keep the product out of reach of children and do not use after the expiry date printed on the packaging.

Imatinib Sandoz is taken orally as a whole tablet with a glass of water. It can be taken with or without food, but patients should follow any specific instructions from their prescriber. Swallow the tablet whole; do not crush, split, or chew unless advised by a healthcare professional.

The most serious adverse events include severe neutropenia or leukopenia, hepatotoxicity with marked elevation of liver enzymes, cardiac failure or reduced left‑ventricular function, and rare but life‑threatening skin reactions such as Stevens‑Johnson syndrome. Patients should be monitored regularly for these conditions and report any concerning symptoms promptly.

Imatinib Sandoz should be avoided in individuals with known hypersensitivity to imatinib or any of its excipients. Patients with severe hepatic impairment, uncontrolled cardiac disease, or those who are pregnant without a clear benefit‑risk justification should not use the product unless closely supervised by a specialist.